Advertisement
| dendritic cell therapy for cancer: Oncothermia: Principles and Practices Andras Szasz, Nora Szasz, Oliver Szasz, 2010-11-23 Oncothermia is the next generation medical innovation that delivers selective, controlled and deep energy for cancer treatment. The basic principles for oncothermia stem from oncological hyperthermia, the oldest approach to treating cancer. Nevertheless, hyperthermia has been wrought with significant controversy, mostly stemming from shortcomings of controlled energy delivery. Oncothermia has been able to overcome these insufficiencies and prove to be a controlled, safe and efficacious treatment option. This book is the first attempt to elucidate the theory and practice of oncothermia, based on rigorous mathematical and biophysical analysis, not centered on the temperature increase. It is supported by numerous in-vitro and in-vivo findings and twenty years of clinical experience. This book will help scientists, researchers and medical practitioners in understanding the scientific and conceptual underpinnings of oncothermia and will add another valuable tool in the fight against cancer. Professor Andras Szasz is the inventor of oncothermia and the Head of St Istvan University's Biotechnics Department in Hungary. He has published over 300 papers and lectured at various universities around the world. Dr. Oliver Szasz is the managing director of Oncotherm, the global manufacturer and distributor of medical devices for cancer treatment used in Europe & Asia since the late 1980s. Dr. Nora Szasz is currently a management consultant in healthcare for McKinsey & Co. |
| dendritic cell therapy for cancer: Cancer Vaccines and Immunotherapy Peter L. Stern, Peter C. L. Beverley, Miles Carroll, 2000-08-17 Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments. |
| dendritic cell therapy for cancer: Vaccines for Cancer Immunotherapy Nima Rezaei, Mahsa Keshavarz-Fathi, 2018-10-17 Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians, scientists, and researchers working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines. Vaccines for Cancer Immunotherapy provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines. - Introduces the feasible immunotherapeutic vaccines for patients with different types of cancer - Presents the status of past and current vaccines for cancer treatment - Considers advantages and disadvantages of different therapeutic cancer vaccines - Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods - Analyzes obstacles to development of therapeutic cancer vaccines - Gives a view on future perspectives in the application of therapeutic cancer vaccines |
| dendritic cell therapy for cancer: Ovarian Cancer Immunotherapy Samir A. Farghaly, 2018-08-31 Ovarian Cancer Immunotherapy provides a broad overview of several aspects of basic sciences, and clinical and therapeutic aspects of immunotherapy for ovarian cancer, as well as state-of-the-art information on molecular genetics and biology. Chapters are written by a team of expert contributors from around the world and explore topics such as antibody therapeutics for ovarian carcinoma, emerging serum biomarkers, ovarian cancer immunity, adoptive cell immunotherapy, the biology of dendritic cells, the role of growth factors, and more. Readers will also gain a better understanding of the molecular and cellular events that underlie ovarian cancer immunology. This book is an ideal resource for clinicians, basic medical scientists, graduate basic medical science students, and medical students caring for patients with ovarian cancer, including attending surgeons and physicians, and clinical fellows and residents in the disciplines of gynecologic oncology, medical oncology, and surgical oncology. |
| dendritic cell therapy for cancer: Translational Immunotherapy of Brain Tumors John H. Sampson, 2017-02-06 Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors. Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike. 2018 BMA Medical Book Awards Highly Commended in Oncology - Comprehensive overview, providing an update on immunology, translational immunotherapy, and clinical trials relating to malignant gliomas - Edited by a prominent neurosurgeon with contributions by leading researchers in the field - Ideal resource for researchers and practitioners interested in learning about mechanisms that use the immune system to treat brain tumors |
| dendritic cell therapy for cancer: Mesothelioma Giovanni Luca Ceresoli, Emilio Bombardieri, Maurizio D'Incalci, 2019-06-19 This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management. Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease’s biology, together with the availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies. This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas – e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials – and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike. |
| dendritic cell therapy for cancer: General Principles of Tumor Immunotherapy Howard L. Kaufman, Jedd D. Wolchok, 2007-10-12 This book brings together the world’s leading authorities on tumor immunology. This book describes the basic immunology principles that form the foundation of understanding how the immune system recognizes and rejects tumor cells. The role of the innate and adaptive immune responses is discussed and the implications of these responses for the design of clinical strategies to combat cancer are illustrated. |
| dendritic cell therapy for cancer: Precision Medicine in Oncology Bulent Aydogan, James A. Radosevich, 2020-11-02 A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others. |
| dendritic cell therapy for cancer: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| dendritic cell therapy for cancer: Targeted Antigen Delivery: Bridging Innate and Adaptive Immunity Bénédicte Manoury, Piergiuseppe De Berardinis, 2019 This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact. |
| dendritic cell therapy for cancer: Immunobiology of Dendritic Cells Part A , 2019-10-04 Immunobiology of Dendritic Cells Part A, Volume 348 in the International Review of Cell and Molecular Biology series highlights new advances in the field, with this new volume presenting interesting chapters on the Origin and Development of Dendritic Cells, Dendritic Cell Subsets and Locations, Antigen Processing and Presentation, The Interaction of Dendritic Cells With Cancer Cells, The Role of Dendritic Cells in Human Diseases, and Dendritic Cells-based Vaccines for Cancer Therapy. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in the International Review of Cell and Molecular Biology series - Includes the latest information on the Immunobiology of Dendritic Cells, Part A |
| dendritic cell therapy for cancer: Advances in Cancer Research , 2018-01-24 Advances in Cancer Research, Volume 137, the latest release in this ongoing, well-regarded serial provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents original reviews on research bridging oncology and gene expression, with this volume covering unconventional approaches to modulating the immunogenicity of tumor cells, tumor dormancy and immunoediting, the emerging role of anti-apoptotic Bcl-2 family proteins in chemoresistance, Beclin-1 and autophagy, MDA-7/IL-24, and nanotechnology and medicine. |
| dendritic cell therapy for cancer: Dendritic Cells in Cancer Michael R Shurin, Russell D. Salter, 2009-04-20 It covers all aspects of DC generation, function, survival and antitumor activity in the tumor environment both in vivo and in experimental in vitro systems. The goal in focusing on a spectrum of issues related to DC in cancer is to provide an extensive and expansive review rather than a collection of independent analyses from different authors. Specific topics to be covered include analysis of DC behavior in the tumor microenvironment, including endogenous and exogenous DC, multiple DC populations, molecular pathways responsible for DC dysfunction, tumor-derived factors altering DC polarization and activation, mechanisms of DC alterations, and the role of DC in tumor escape from immune recognition and elimination. Furthermore, additional chapters provide extensive analysis of the consequences of cancer therapy on the DC system and how aging impacts DC function in the tumor microenvironment. Finally, chapters are included examining strengths and pitfalls of current methodologies for generating DC from cancer patients for therapeutic purposes and on the role of tumor-mediated modulation of the DC system in cancer immunotherapy. |
| dendritic cell therapy for cancer: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors Jessica Dal Col, Alejandro López-Soto, Riccardo Dolcetti, 2020-06-04 |
| dendritic cell therapy for cancer: Interaction of Immune and Cancer Cells Magdalena Klink, Izabela Szulc-Kielbik, 2022-02-14 Now, it its second edition, this book summarizes the role of immune cells in tumor suppression and progression. It describes in detail why tumor cells can survive and spread in spite of the antitumor response of immune cells. Since immunotherapy is an attractive approach to cancer therapy, this book also provides information on the two main strategies: monoclonal antibodies and adaptive T cell immunotherapy, with a focus on recent human clinical trials. A newly added chapter also focuses on the role of Natural Killer cells in tumor progression. The book provides a state-of-the-art, comprehensive overview of immune cells in cancer and is an indispensable resource for researchers and practitioners working or lecturing in the field of cancer research and immunology. |
| dendritic cell therapy for cancer: Advances in Precision Medicine Oncology Hilal Arnouk, Bassam Abdul Rasool Hassan, 2021 Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects. |
| dendritic cell therapy for cancer: Cancer Vaccines Michael J.P. Lawman, Patricia D. Lawman, 2014-03-12 Cancer Vaccines: Methods and Protocols explores the manipulation and modification of immune cells, the manipulation and modification of tumor cells as well as the manipulation of immune/tumor interactions and various delivery mechanisms, with the overall end goal of evoking a tumor-specific response and overcoming the immuno-evasive mechanisms employed by the tumor cells. This detailed volume also covers the subject of cancer vaccines in a more global sense with its section on the advances, challenges, and future of cancer vaccines. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols and tips on troubleshooting and avoiding known pitfalls. Comprehensive and authoritative, Cancer Vaccines: Methods and Protocols aims to help guide researchers toward developing further generations of cancer vaccines that are both safe and efficacious, with the hope that cancer vaccines will be the standard of care in the very near future. |
| dendritic cell therapy for cancer: Immuno-oncology Olivier Michielin, George Coukos, 2015 Over the last decade, immuno-oncology has witnessed an astonishing pace of discovery and innovation translating into unprecedented successes in the clinical setting, arguably representing one of the most profound and transforming revolution in the history of cancer therapy. This book provides a concise and accurate outline of the main developments in major tumor types including melanoma, lung, breast, brain and renal cell cancers. In addition, transversal chapters that describe the commonalities of some of the therapeutic strategies are provided to cover topics like immune checkpoint biology, T cell engineering or rational combination therapies. Each chapter has been authored by senior key opinion leaders in their respective fields to provide the most up-to-date view on cancer immuno-oncology. To reflect on the key translational aspect of immuno-oncology, all chapters are making explicit connections between basic science discoveries and the resulting translational therapeutic strategies. Immuno-Oncology will be an invaluable source of information for scientists interested in the translation of basic immunology into the clinical practice, as well as for clinician interested in deepening their knowledge of current and upcoming immune strategies in the fight against cancers. |
| dendritic cell therapy for cancer: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| dendritic cell therapy for cancer: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| dendritic cell therapy for cancer: Genes and Resistance to Disease Victor Boulyjenkov, Kåre Berg, Yves Christen, 2000 The advances in human genetics that have ocurred during the past 20 years have revolutionized our knowledge of the role played by inheritance in health and disase. It is clear that our DNA determines not only the emergence of catastrophic single-gene disorders, which affect millions of persons worldwide, but also interacts with environments to predispose individuals to cancer, allergy, hypertension, heart disease, diabetes, psychiatric disorders and even to some infectious diseases. Overall, the study of longevity and the demonstration of genes favouring a long lifespan suggest that such protective systems exist. In recent years, the study of genetic polymorphisms has made clear that some alleles have beneficial effects. These discoveries can substantially improve our understanding of the interactions between genetics and the environment, between pathogenetic mechanisms and new treatments. |
| dendritic cell therapy for cancer: Tumor Immunology and Immunotherapy Robert C. Rees, 2014 Tumor immunology and immunotherapy provides a comprehensive account of cancer immunity and immunotherapy. Examining recent results, current areas of interest and the specific issues that are affecting the research and development of vaccines, this book provides insight into how these problems may be overcome as viewed by leaders in the field. |
| dendritic cell therapy for cancer: Brain Tumor Immunotherapy Linda M. Liau, Donald P. Becker, Timothy F. Cloughesy, Darell D. Bigner, 2000-11-10 An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics. |
| dendritic cell therapy for cancer: Monoclonal Antibodies in Cancer Stewart Sell, Ralph Reisfeld, 2012-12-06 This represents the third volume in a series on cancer markers pub lished by the Humana Press. The first volume, published in 1980, stressed the relationship of development and cancer as reflected in the production of markers by cancer that are also produced by normal cells during fetal development. The concept that cancer represents a problem of differentiation was introduced by Barry Pierce in describing differenti ation of teratocarcinomas. Highlighted were lymphocyte markers, alphafetoprotein, carcinoembryonic antigen, ectopic hormones, enzymes and isozymes, pregnancy proteins, and fibronectin. The second volume, published in 1982 and coedited with Britta Wahren, focused on the diagnostic use of oncological markers in human cancers, which were systematically treated on an organ by organ basis. At that time, the application of monoclonal antibodies to the identification of cancer markers was still in a very preliminary stage. A general introduc tion to monoclonal antibodies to human tumor antigens was given there by William Raschke, and other authors included coverage of those mark ers then detectable by monoclonal antibodies in their chapters. |
| dendritic cell therapy for cancer: A Historical Perspective on Evidence-Based Immunology Edward J. Moticka, 2015-11-25 A Historical Perspective on Evidence-Based Immunology focuses on the results of hypothesis-driven, controlled scientific experiments that have led to the current understanding of immunological principles. The text helps beginning students in biomedical disciplines understand the basis of immunologic knowledge, while also helping more advanced students gain further insights. The book serves as a crucial reference for researchers studying the evolution of ideas and scientific methods, including fundamental insights on immunologic tolerance, interactions of lymphocytes with antigen TCR and BCR, the generation of diversity and mechanism of tolerance of T cells and B cells, the first cytokines, the concept of autoimmunity, the identification of NK cells as a unique cell type, the structure of antibody molecules and identification of Fab and Fc regions, and dendritic cells. - Provides a complete review of the hypothesis-driven, controlled scientific experiments that have led to our current understanding of immunological principles - Explains the types of experiments that were performed and how the interpretation of the experiments altered the understanding of immunology - Presents concepts such as the division of lymphocytes into functionally different populations in their historical context - Includes fundamental insights on immunologic tolerance, interactions of lymphocytes with antigen TCR and BCR, and the generation of diversity and mechanism of tolerance of T and B cells |
| dendritic cell therapy for cancer: Tertiary Lymphoid Organs (TLOs): Powerhouses of Disease Immunity Changjun Yin, Andreas J.R. Habenicht, Sarajo Mohanta, Pasquale Maffia, 2017-05-22 The immune system employs TLOs to elicit highly localized and forceful responses to unresolvable peripheral tissue inflammation. Current data indicate that TLOs are protective but they may also lead to collateral tissue injury and serve as nesting places to generate autoreactive lymphocytes. A better comprehension of these powerhouses of disease immunity will likely facilitate development to unprecedented and specific therapies to fight chronic inflammatory diseases. |
| dendritic cell therapy for cancer: Dendritic Cells in Cancer Michael R Shurin, Russell D. Salter, 2009-04-14 It covers all aspects of DC generation, function, survival and antitumor activity in the tumor environment both in vivo and in experimental in vitro systems. The goal in focusing on a spectrum of issues related to DC in cancer is to provide an extensive and expansive review rather than a collection of independent analyses from different authors. Specific topics to be covered include analysis of DC behavior in the tumor microenvironment, including endogenous and exogenous DC, multiple DC populations, molecular pathways responsible for DC dysfunction, tumor-derived factors altering DC polarization and activation, mechanisms of DC alterations, and the role of DC in tumor escape from immune recognition and elimination. Furthermore, additional chapters provide extensive analysis of the consequences of cancer therapy on the DC system and how aging impacts DC function in the tumor microenvironment. Finally, chapters are included examining strengths and pitfalls of current methodologies for generating DC from cancer patients for therapeutic purposes and on the role of tumor-mediated modulation of the DC system in cancer immunotherapy. |
| dendritic cell therapy for cancer: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| dendritic cell therapy for cancer: Treatment of Bone and Soft Tissue Sarcomas Per-Ulf Tunn, 2008-12-28 Bone and soft tissue sarcomas represent only about 2% of all malignancies; however, their treatment – with the goal of curing the patient while preserving the functionality of the affected body part – can, unlike other malignancies, only be successful with therapy concepts devised by interdisciplinary teams. This volume provides an extensive up-to-date overview of the specific diagnostics and current treatment standards of these rare entities, presenting the various limb-sparing modalities for patients with bone and soft tissue sarcomas with special regard to innovative reconstructive options. The evaluation of quality of life based on validated scores and the individual methods of coping with the illness through creative artistic projects are also acknowledged and integrated in the whole concept. |
| dendritic cell therapy for cancer: Adoptive Immunotherapy Burkhard Ludewig, Matthias W. Hoffmann, 2008-02-02 An authoritative collection of optimal techniques for producing and characterizing the immunologically active cells and effector molecules now gaining wide use in the clinical treatment of patients. Taking advantage of the latest technologies, the authors present readily reproducible experimental protocols for the study of dendritic cells, T cells, monoclonal antibodies, and bone marrow transplantation. The emphasis is on preclinicical and clinical applications and on the progress of selected approaches in clinical trials. Additional chapters cover the molecular definition of target antigens, mathematical modeling approaches to immunotherapy, and the utilization of regulatory T cells. The protocols make it possible to study the adoptive transfer of tailored antigen-specific immune cells and to improve the clinical application of adoptive immunotherapy. |
| dendritic cell therapy for cancer: Crossroads Between Innate and Adaptive Immunity V Stephen P. Schoenberger, Peter D. Katsikis, Bali Pulendran, 2015-08-31 This volume presents a collection of reviews derived from work presented at the Aegean Conference: “5th Crossroads Between Innate and Adaptive Immunity”. This meeting was the fifth in a series, and assembled a team of scientists working on mechanisms by which the innate immune system of the host senses pathogens, the cellular and signaling networks that orchestrate the innate response and antigen presentation and adaptive immunity. The importance of the crosstalk between innate immunity and the adaptive immune response has only recently started to be appreciated. Although it is well recognized that dendritic cells, NK cells, NK-T cells and T cells are all critical for the host response to pathogens, the respective fields that study the biology of these immune cells tend to exist in parallel worlds with minimum exchange of information and ideas. This fragmentation hinders the integration of these fields towards a unified theory of host response. The Aegean Conference “Crossroads between Innate and Adaptive Immunity” brought together leading international scientists and experts to address critical areas of Innate and Adaptive Immunity, a necessary step in the development of more efficient scientific exchange and crosspollination between these fields. This conference attracted scientists from all over the world to discuss their latest findings on the various aspects of Innate and Adaptive Immunity, and maximized scientific interchange through lecture presentations, poster sessions and informal discussions. |
| dendritic cell therapy for cancer: Cancer Immunology and Immunotherapy Glenn Dranoff, 2011-04-11 The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment. |
| dendritic cell therapy for cancer: Dendritic Cells in Clinics Morikazu Onji, Sk. Md. Fazle Akbar, 2013-06-29 Great advances have taken place in basic research and the clinical usefulness of dendritic cells (DCs). It has now been clearly established, for instance, that these cells play a crucial role in immune responses against infectious diseases and cancers. Antigen-presenting DCs are widely distributed in the body and regulate both immunity and immune tolerance. Experimental studies have provided important insights into DCs and how they can be used for treating animal models of various diseases that occur in humans. The role of these cells in pathogenesis and the treatment of human diseases is elaborately set forth in this valuable book. Researchers in the field are optimistic that DCs, already in use for treating patients with cancers, soon can be used therapeutically for patients with chronic infections, autoimmune diseases, and allergic manifestations. This volume provides a working definition of DCs and also explains the phenotypes and functions of DCs so that these can be readily understood not only by clinicians but by immunologists, researchers, and students as well. |
| dendritic cell therapy for cancer: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| dendritic cell therapy for cancer: Regulation of the Immune Response Pearay L. Ogra, Diane M. Jacobs, 1983 |
| dendritic cell therapy for cancer: Tertiary Lymphoid Structures Marie-Caroline Dieu-Nosjean, 2018-09-05 This volume explores the various methods used to study tertiary lymphoid structures (TLS) in pathological situations. Pre-clinical models are also discussed in detail to show how TLS structure, development, and maintenance can be targeted and studied in vivo. The chapters in this book cover topics such as humans and mice; strategies to quantify TLS in order to use it in stained tissue sections; classifying a gene signature form fixed and paraffin-embedded tissues; and development of murine inflammatory models to help look at TLS in the context of infection or malignancy. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and thorough, Tertiary Lymphoid Structures: Methods and Protocols is a valuable resource that increases the reader’s knowledge on immune functions and how they will pave the way to future therapeutic applications. |
| dendritic cell therapy for cancer: Fighting Cancer Robert Gorter, Erik Peper, 2011 Emphasizing the need for a new model of cancer treatment that nurtures the body's intrinsic cancer fighting mechanisms, Fighting Cancer presents an innovative, non-toxic approach to healing this rampant disease--Provided by Publisher. |
| dendritic cell therapy for cancer: Involvement of dendritic cells in gastrointestinal cancer Ling Ni, Haidong Tang, Mi Deng, Musheng Bao, Jingtao Chen, 2023-04-13 |
| dendritic cell therapy for cancer: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| dendritic cell therapy for cancer: Dendritic Cell Control of Immune Responses Penelope Anne Morel, Lisa Helene Butterfield, 2016-07-27 Dendritic cells (DC) are among the first cells to encounter pathogens and damage in peripheral tissues and, upon activation, DC migrate to lymph nodes where they activate and educate T cells to initiate and shape the immune response. DC present pathogen-derived antigen to T cells and drive T cell differentiation into particular effector cells through the expression and secretion of co-stimulatory molecules and cytokines respectively. The study of DC biology has included the identification of multiple DC subsets in tissues and lymphoid organs, the differentiation and plasticity of DC subsets, the functional consequences of DC interaction with pathogen, control of DC migratory properties and the impact of DC on T cell activation and differentiation. In recent years sophisticated systems biology approaches have been developed to deepen our understanding of DC function. These studies have identified differences between DC subsets located in various tissues and critical factors that drive the outcome of the interaction between DC and T cells. DC are currently being used in in various clinical therapeutic settings, including as vaccines for cancer and autoimmune disease. A clear understanding of DC factors that contribute to specific immune responses is vital to the success of DC based therapies. This research topic will give a comprehensive overview of current issues in DC biology and provides an update on the clinical uses of DC in the therapy of autoimmunity and cancer. |
Dendritic cell - Wikipedia
Dendritic cells are present in tissues that are in contact with the body's external environment, such as the skin, and the inner lining of the nose, lungs, stomach and intestines. They can also be …
DENDRITIC Definition & Meaning - Merriam-Webster
The meaning of DENDRITIC is resembling or having dendrites : branching like a tree. How to use dendritic in a sentence.
Dendritic Cells - The Definitive Guide | Biology Dictionary
Jul 17, 2020 · Dendritic cells are named after their shape and are not neurons with dendrites, as was thought when first discovered in the late nineteenth century. They are bone marrow and …
Review of Dendritic Cells, Their Role in Clinical Immunology, and ...
Dendritic cells (DCs) are cells derived from the hematopoietic stem cells (HSCs) of the bone marrow and form a widely distributed cellular system throughout the body.
Dendritic Cells- Definition, Structure, Immunity, Types, Functions
Apr 30, 2022 · Dendritic cells represent a distinct type of white blood cells capable of alerting the immune system about the presence of infections and activating the innate and adaptive …
Dendritic Cells | British Society for Immunology
Dendritic cells (DCs), named for their probing, ‘tree-like’ or dendritic shapes, are responsible for the initiation of adaptive immune responses and hence function as the ‘sentinels’ of the …
Dendritic Cells: Origins, Differentiation, and Immune Functions
Apr 29, 2025 · Explore the origins, differentiation, and immune roles of dendritic cells, highlighting their crucial functions in the body's defense mechanisms. Dendritic cells are key components …
Dendritic Cells: Dendritic Cell Origin, Function and Related …
Mar 19, 2024 · In this article, we consider what dendritic cells are, how they are generated, their function in the body and some medical conditions related to them.
Dendritic Cells: Definition, Subsets, Function & Significance
Dendritic cells (DCs) are a type of immune cell that plays a critical role in initiating and regulating immune responses. They act as sentinels, constantly patrolling the body for foreign invaders …
The Dendritic Cell Lineage: Ontogeny and Function of Dendritic …
Dendritic cells (DCs) form a remarkable cellular network that shapes adaptive immune responses according to peripheral cues. After four decades of research, we now know that DCs arise …
Oncolytic Virus-Based Anti-Cancer Therapy in combination …
Oncolytic Virus-Based Anti-Cancer Therapy in combination with DCT ( dendritic cell therapy) "In the treatment of tumour diseases, it is becoming increasingly clear that there is neither 'the …
Cell Therapy - SingHealth
Cell Therapy Centre and Assistant Medical Director at the Cell Therapy Facility, Health Sciences Authority. She spent two years training at the MD Anderson Cancer Center in CAR T-cell …
Dendritic Cell Therapy in the palliative Treatment of …
dendritic cell therapy and 13 months from first diagnosis of pancreatic cancer (fig. 1, tab.1). Fig.1 : Kaplan-Meier survival analysis of advanced pancreatic cancer patients (n=200) treated with ...
The Progress and Prospects of Immune Cell Therapy for the …
killer (CIK) cell therapy, dendritic cell (DC) vaccines, and DC/CIK cell therapy are designed to use the body’s natural defense mechanisms to target and eliminate cancer cells, and usually have …
Immuno-cell Therapy of Cancer in Japan - Anticancer Research
The immuno-cell therapy of cancer in Japan is in the phase of transition from therapeutic research to a more generalized option for all patients. A short history of cancer ... dendritic cell …
Blastic Plasmacytoid Dendritic Cell Neoplasm - Leukemia
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as natural killer (NK) cell leukemia/ ... therapy for BPDCN patients. Standard care consists of AML-like or acute …
Enhancing Dendritic Cell Therapy in Solid Tumors with …
Review Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment Robert A. Belderbos, 1,2Joachim G.J.V. Aerts, and Heleen Vroman1,2 1Department …
Additional Long Antigen Exposition Dendritic Cell Therapy …
We have recently reported about the beneficial effects of dendritic cell therapy using DC in the additional palliative treatment of patients suffering from pancreatic cancer [10]. In the following
Dendritic Cell Cancer Therapy: Vaccinating the Right
the position of dendritic cell therapy in the treatment landscape of cancer. In this review, we address some key questions regarding the integration of dendritic cell vaccination in future …
Dendritic Cell Therapy - immunyo.com
as one of the most significant breakthroughs in the fight against cancer, providing new hope for patients. Dendritic Cell Therapy harnesses the remarkable ability of dendritic cells to activate …
Dendritic cell–derived exosomes for cancer therapy
the feasibility and safety of the approach, as well as the propensity of these nanovesicles to mediate T and NK cell–based immune responses in patients. This Review will evaluate the …
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell …
Fig. S1. Related to Figure 1. Characterization of IFN-!+ CD8+ T Cells and IL-12p40+ DCs After aPD-1 Therapy. (A) Quantification of IFN-! signal from intravital microscopy of IFN-! reporter …
Challenges and Opportunities for Pancreatic Cancer ... - Cell …
PDA to ICB therapy (Henriksen et al., 2019)(Figure 1). Indeed, non-redundant immune-modulatory agents such as autophagy inhibition to restore tumor cell MHC-I expression (Yamamoto et al., …
Fascin actin-bundling protein 1 in human cancer: Promising
formation in cultured cells by recruiting fascin as an effector protein. In addition to the above interaction partners, various proteins have been found to physiologically interact with …
Engineering dendritic cell biomimetic membrane as a …
sion of T cell activity, these include melanoma, renal cell carcinoma (RCC), lung cancer, and squamous cell carci-noma of the head and neck, among others [8]. Dual ICI therapy or …
Personalized neoantigen pulsed dendritic cell vaccine for
Dendritic cell (DCs) vaccines based on neoantigens have exciting effects in treatment of some malignant tumors ... Several strategies, such as ICIs, adoptive cell therapy (ACT) and cancer …
Immune activation by combination human lymphokine …
Aug 16, 2011 · killer and dendritic cell therapy EJ West 1,2 , KJ Scott 1,2 , VA Jennings 1 and AA Melcher* ,1 1 Cancer Research UK Clinical Centre, St James’s University Hospital, Beckett …
Orchestrating an immune response to cancer with cellular
conventional dendritic cell (cDC1) transcriptome until day 9. Tumour-APCs lose tumorigenicity and upregulate antigen presentation machinery (MHC-I, MHC-II and costimulatory molecules) that …
Black phosphorus-based nanoparticles induce liver cancer cell ...
PLGA@BP-R848 nanoparticles bolster immune cell infiltration into tumors and induce cancer cell apoptosis. The synergistic therapy involving dendritic cells and photothermal nanoadjuvant …
New lipid nanoparticle-mRNA therapy combats melanoma in …
dendritic cells for cancer immunotherapy to treat a wide range of solid ... lipid nanoparticle-mRNA formulations and dendritic cell therapy, Nature Nanotechnology (2023). DOI: 10.1038/s41565 …
Dendritic cell vaccines extend CAR T‐cell persistence and …
T-cell therapy.2 Dendritic cell (DC) vaccination is well tolerated and thus is a promising therapy related to cancer-specific cytotoxic lym-phocytes (CTLs), which may prevent recurrence. …
PD-1/TIM-3 to treat lung cancer therapy synergizes with …
Dendritic cell (DC) therapy is a potential candidate to solve these problems.6–9 DCs are professional antigen presenting cells of innate immunity to initiate antigen-specic T cell …
Perilymphatic regulatory T cell-dendritic cell ... - Cell Press
Perilymphatic regulatory T cell-dendritic cell interactions represent a novel axis of ... Cancer Cell 42, August 12, 2024 ª 2024 Elsevier Inc. 1329 ... multimodal therapy, including surgery followed …
The Landscape of Cell and Gene Therapies for Solid Tumors
Adoptive cell therapy (ACT) takes advantage of immune cells to eliminate tumors. ACT can be broadly classified as non-genetically and genetically engi-neered cell products or classified …
Individualized cancer therapy with specific activation of the
The dendritic cells receive the necessary information about the cancer cells while outside the body. Through a specific method, they are confronted in the test tube with dead and especially …
Personalized Dendritic-cell-based Vaccines Targeting Cancer …
peptides and mRNA and dendritic-cell (DC)-based vaccines. Personalized DC-based vaccines not only can load various antigens including neoantigens, but also have the potential to ...
Overcome cancer from within Dendritic Cell Therapy DCT
FAQ about Dendritic Cell Therapy 1. Am I eligible for Dendritic Cell Therapy? The mechanism of action of Dendritic Cells remains consistent across cancer types, including solid tumours …
Dendritic cells in cancer immunology and immunotherapy
counterparts in transcriptional and main functional analyses9,18 +(Table 1); however, these comparisons have to be evaluated with caution. For example, single-cell RNA sequencing …
Best Dendritic Cell Therapy Laboratory 2021 - labor …
Best Dendritic Cell Therapy Laboratory 2021 The LDG GmbH produces dendritic cell therapies for the treatment of cancer, with most of its patients finding their way directly to the firm due to its …
Enhancing Dendritic Cell Therapy in Solid Tumors with …
Review Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment Robert A. Belderbos, 1,2Joachim G.J.V. Aerts, and Heleen Vroman1,2 1Department …
Tumor eradication by hetIL-15 locoregional therapy ... - Cell …
CD103intCD11b+ dendritic cell population Graphical abstract Highlights d hetIL-15 locoregional administration eradicates EO771 ... Tumor eradication by hetIL-15 locoregional therapy …
T Cell Cancer Therapy Requires CD40-CD40L Activation of
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells ... (TNF)-producing dendritic cells (DC), or Tip …
Tumor-Residing Batf3 Dendritic Cells Are Required for
Cancer Cell Article Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive TCellTherapy Stefani Spranger,1 Daisy Dai,1 Brendan Horton,1 and …
Dendritic Cell Vaccines in Ovarian Cancer - Frontiers
Keywords: dendritic cells (DCs), ovarian cancer (OC), immunotherapy, tumor microenvironment, dendritic cell vaccine INTRODUCTION Ovarian cancer is the most lethal gynecological cancer, …
Comprehensive analysis of FKBP4/NR3C1/TMEM173 signaling …
signaling pathway in triple-negative breast cancer cell and dendritic cell among tumor microenvironment Hanchu Xiong, 1,3Zihan Chen,2 Baihua Lin, 1,3 Weijun Chen, Qiang Li, …
Insights Into Dendritic Cells in Cancer Immunotherapy: From …
relying on cell therapy, cancer inhibitory signal antagonists, nanoparticle-based vaccines, oncolytic viruses, and immunogenic cell death-inducing agents, is considered a cornerstone in …
Blastic Plasmacytoid Dendritic Cell Neoplasm: Update on …
Blastic Plasmacytoid Dendritic Cell Neoplasm: ... and Therapy Wasif Riaz, MD, Ling Zhang, MD, Pedro Horna, MD, and Lubomir Sokol, MD, PhD Background: Blastic plasmacytoid dendritic …
An iPSC-derived exosome-pulsed dendritic cell vaccine
EGFR is a tyrosine kinase receptor that mediates cell growth, differ-entiation, and survival signals, which is mutated or overexpressed in many solid tumors, such as lung cancer, breast cancer, …
REVIEW Dendritic cell-based vaccine: a promising approach …
Dendritic cell-based vaccine: a promising approach for cancer immunotherapy K Tarte 1 and B Klein 1,2 1 INSERM U 475, Montpellier; and 2 Unit For Cellular Therapy, CHU Saint Eloi, …
Cancer Science & Therapy - Hilaris Publishing SRL
as erysipelas [4]. Nearly a century later the mechanism of dendritic cell’s immune activation and pathogen recognition was better elucidated [1]. The immunotherapy can be divided into …
T Helper 17 Cells Promote Cytotoxic T Cell Activation in …
efficacy than Th1 cells. Unexpectedly, therapy using Th17 cells elicited a remarkable activation of tumor-specific CD8+ T cells, which were necessary for the antitumor effect. Th17 cells …
The Dendritic Cell Strikes Back - Cell Press
In this issue of Immunity, Garris et al. (2018) show that the efficacy of anti-PD-1 therapy depends on a T-cell-dendritic-cell (DC) licensing loop fueled by IFN-g and IL-12, thereby establishing a …
Review Article Role of hypoxia in inhibiting dendritic cells by …
dendritic cell (DC) differentiation and matura-tion, resulting in a poor immune response [6, 7] and making DCs a crucial target for tumors to escape immunosurveillance mechanisms [8]. …
Autologous Dendritic Vaccine Therapy in Metastatic Kidney …
Clinical Studies Update Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond Viraj A. Mastera,*, Robert G. Uzzob, Gennady Bratlavskyc, Jose A. …
Landscape of cancer cell therapies: trends and real-world …
Jun 1, 2022 · Changes in the cancer cell therapy pipeline by year, both in terms of number of agents (orange bars) and number of targeted proteins (blue line). ... (TSA) and (7) therapies …
TLR5 Signaling Causes Dendritic Cell Dysfunction and …
TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates the Failure of Immune Checkpoint Therapy Against Ovarian Cancer Mitchell Thomas McGinty Clifton, Virginia B.S., …
Facts About Blastic Plasmacytoid Dendritic Cell Neoplasm …
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive, historically difficult-to-diagnose . hematologic malignancy with a poor prognosis. In recent years, better …
TIM-3 Regulates CD103+ Dendritic Cell Function and …
Cancer Cell Article TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer A´lvaro de Mingo Pulido,1 Alycia Gardner,1,2 Shandi Hiebler,1 …
CXCL9/10-engineered dendritic cells promote T cell ... - Cell …
CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer ... potential therapy for non-small cell lung cancer (NSCLC). IT …
Dendritic cell vaccines as cancer treatment: focus on 13 …
cell therapy clinical trials dendritic cell-based vaccine GMP manufacturing release parameter Introduction Advanced therapy medicinal products (ATMPs) represent an inno-vative category …
